Howard J. Leonhardt

VascuStim is a company that specializes in bioelectric signaling technologies for regeneration, healing, and recovery. The company is based in Santa Monica, CA. The company's focus is on bioelectric and light therapy stimulation. The CEO of the company is Howard J. Leonhardt.

Ear-Cell is a company that utilizes bioelectric stimulation to control the release of specific proteins for regenerative purposes. The company is based in Los Angeles, CA and was founded in 2016 by Howard J. Leonhardt. The company has a sequence of proteins that they use for stem cell homing, DNA repair, tissue loosening, increasing elasticity, and promoting wound healing. The company also has special signals to stop tumor cell division and blood supply in cases of ear cancer.

RegenaLung is an American company founded in 2015 with Richard Koffler as the CEO. The company's focus is on developing innovative solutions for lung diseases using regenerative medicine. RegenaLung's technology involves the use of stem cells to repair damaged lung tissue and improve lung function. The company's mission is to improve the lives of patients suffering from lung diseases by providing effective and safe treatments. RegenaLung is committed to advancing the field of regenerative medicine and bringing new therapies to market.

SkinStim manufactures bioelectric stimulation products. The American company was founded in 2015 by Howard J. Leonhardt. Howard J. Leonhardt has been the CEO since 2015.

KidneyCell is an American company that develops non-invasive bioelectric stimulation for kidney recovery. The company was founded by Howard J. Leonhardt, who has been the CEO since incorporation.

BladderCell is a company that focuses on developing a therapy for urinary incontinence. The company is based in Salt Lake City, UT, and the CEO of the company is Howard J. Leonhardt. The company uses bioelectric signals to recruit, proliferate, and differentiate stem cells into bladder muscle, as well as to control the release of proteins for regenerating bladder function. BladderCell's proprietary BC-15 composition includes stem cells, myoblasts, exosomes, matrix, and other support factors that regenerate muscle, urothelium, and restore elasticity.

InstimCell is an early stage startup that focuses on customized inflammation management with bioelectric stimulation. The American company believes that it can restart a person's chronic inflammation cycle by deriving ideal optimal healing cycles from healthy subjects that have an inflammation-causing event and recover quickly and fully. InstimCell licenses its technology to other startups within Leonhardt's Launchpads accelerators for specific organ applications such as brain injury recovery, pancreas regeneration recovery from pancreatitis, bioelectric cancer treatments, and chronic heart failure recovery. The company was founded by Howard J. Leonhardt, who has been the CEO since incorporation.

Valvublator is a medical company that rebuilds heart valve leaflets and orifice using a patient's own cells. The company is based in Salt Lake City, UT. The process involves decalcifying, cell sodding, regenerating, surface modifying, and strengthening the heart valve. The company also provides embolitic fragment protection throughout the procedure, ultrasonic cleaning, vacuum removal of debris, and microcurrent regeneration signal that recruits stem cells with homing signal and differentiates them to valve tissue. Valvublator was founded in 1988 by Leslie Miller and Howard J. Leonhardt, and Howard J. Leonhardt has been the CEO since 1988.

AddictiStim provides bioelectric stimulation addiction treatment technology services. The company is based in Irvine, CA. The CEO of the company is Howard J. Leonhardt.

TremorStim is a company that specializes in bioelectric signaling to control specific protein expressions or suppressions that help reduce essential tremor movements and duration. The company is based in Irvine, CA, and the CEO of the company is Howard J. Leonhardt. The company offers the TremorStim II treatment protocol, which includes a wrist band, brain band, focused ultrasound, and bodstim exercises. The second-generation system is designed to be miniaturized and wireless, with a comfortable bioelectric watch or glove for the hand/wrist and small bioelectric micro stimulators placed on a patient's upper neck, lower base of the brain, or behind the ears, generally not visible.

DentaCell Accelerator is an organization that was converted into an accelerator in 2017 to address innovations in dentistry and support multiple startup launches simultaneously. The company is based in Los Angeles, CA. The company provides access to Leonhardt's Launchpads' building IP estate in stem cell, growth factors, micro pumps, and bioelectric stimulation technologies. The company also offers access to Cal-X Stars Business Accelerator, Inc. network of successful entrepreneurs, investors, mentors, and corporate partners. The company focuses on electroceutical treatment of pseudomonas aeruginosa biofilms. The company was founded in 2014, and the CEO is Howard J. Leonhardt.

OrthoStim, a company under Leonhardt Ventures LLC, offers a technology platform that utilizes bioelectric stimulation and stem cell-based compositions to promote the body's own healing potential. OrthoStim is based in Irvine, CA, and is led by CEO Howard J. Leonhardt. The company aims to regenerate joints and eliminate joint arthritis pain through bioelectric stimulations and protein expressions for inflammation management, healing, pain relief, and regeneration promotion. OrthoStim's technology platform includes patented customized inflammation management and a proprietary biologics mix that includes bioelectric pre-treated PRF, secretome from amniotic sourcing, selected exosomes, and patent-pending klotho expressing MSCs. The company targets knee, hip, elbow, tendon, cartilage, bone, and muscle indications. However, the products described on the company's website are still in early stage development and are not yet proven safe or effective in statistically significant controlled clinical studies.